ERBB2 and breast carcinoma: For luminal B HER2 positive subtype, 12 miRNAs had significant differential expression (P ≤ 0.05, 1.5-fold), including 8 miRNAs that were downregulated and 4 miRNAs that were upregulated in serum of cases with breast cancer in comparison with matched healthy controls (Figure 3).